抗HCV小分子化合物的研究

Abstract

The current standard treatment for hepatitis C virus (HCV) infection is a combination of pegylated interferon (PEG-IFN) and ribavirin. However, it remains incurable in some patients. In recent years, direct acting antiviral agents (DAAs) that target specific HCV enzymes in HCV life cycle have been developed rapidly. A combination of PEG-IFN, ribavirin, and DAAs can increase the sustained virological response rate in patients with chronic hepatitis C (CHC). For patients who cannot use or tolerate interferon therapy, a combination of various DAAs has good efficacy. Therefore, DAAs bring new hope for the treatment of CHC